Trial reportAntimicrobial agents and chemotherapy2001
Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
Trial report in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Systemic antibiotics for treating diabetic foot infections.The Cochrane database of systematic reviews · 2015Pooled it
- Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds.The Cochrane database of systematic reviews · 2013Pooled it
- Interventions for cellulitis and erysipelas.The Cochrane database of systematic reviews · 2010Pooled it
- A systematic review and meta-analysis of randomized controlled trials of systemic antibiotics for diabetes-related foot infections.Diabetes & vascular disease researchPooled it
- Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomised controlled trial.Emergency medicine journal : EMJ · 2005Trial
- Ampicillin sulbactam impacts serum potassium level comparable to piperacillin tazobactam.Scientific reports · 2025Observational
- Targeting Anaerobic Respiration inAdvances in wound care · 2024Article
- Brazilian Society of Angiology and Vascular Surgery 2023 guidelines on the diabetic foot.Jornal vascular brasileiro · 2024Article
- Systemic Antimicrobial Therapy for Diabetic Foot Infections: An Overview of Systematic Reviews.Antibiotics (Basel, Switzerland) · 2023Review
- Beta-Lactam vs. Fluoroquinolone Monotherapy forAntibiotics (Basel, Switzerland) · 2021Article
- Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.Antimicrobial agents and chemotherapy · 2016Article
- Isolation and Antibiotic Susceptibility of the Microorganisms Isolated from Diabetic Foot Infections in Nemazee Hospital, Southern Iran.Journal of pathogens · 2015Article
- From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.Current infectious disease reports · 2012Article
- Diagnostics and treatment of the diabetic foot.Endocrine · 2012Review
- In vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.Annals of clinical microbiology and antimicrobials · 2005Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients (n = 409) with severe skin and soft tissue infections (SSTIs) were randomized to receive clinafloxacin or piperacillin-tazobactam (plus optional vancomycin for methicillin-resistant cocci), administered intravenously, with the option to switch to oral medication. Most patients had cellulitis, wound infections, or diabetic foot infections. Staphylococcus aureus, Enterococcus faecalis, and Pseudomonas aeruginosa were the most common baseline pathogens. Fewer baseline pathogens were resistant to clinafloxacin (1.8%) than to piperacillin-tazobactam (6.2%) (P = 0.001). The clinafloxacin and piperacillin-tazobactam groups did not differ significantly in clinical cure rates (68.8 and 65.2%, respectively) or microbiologic eradication rates (61.5 and 57.2%). Clinafloxacin yielded higher eradication rates for all three of the most common pathogenic species, although no differences were statistically significant. Within the power of this study, the overall frequency of adverse events was similar (P = 0.577) in the two treatment groups. Drug-associated adverse events (P = 0.050) and treatment discontinuations (P = 0.052) were marginally more frequent in the clinafloxacin group, primarily due to phototoxicity in outpatients receiving clinafloxacin. Although most cases of phototoxicity were mild to moderate, four cases were reported as severe. In summary, clinafloxacin monotherapy was equivalent in effectiveness to therapy with piperacillin-tazobactam plus optional vancomycin in the treatment of hospitalized patients with severe SSTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.